Trump Administration Reschedules Cannabis, Removing Schedule I Classification

Event summary

  • The U.S. federal government has rescheduled cannabis from Schedule I to Schedule III under the Controlled Substances Act.
  • The rescheduling was finalized by the Trump administration on April 23, 2026.
  • Jushi Holdings Inc. publicly applauded the decision, citing its potential to unlock research and investment.
  • The move does not legalize cannabis at the federal level but removes certain restrictions and penalties.

The big picture

The rescheduling of cannabis represents a significant policy shift, potentially easing financial burdens and opening avenues for research and investment within the industry. While not legalization, the move signals a gradual normalization of cannabis, which could benefit multi-state operators like Jushi. However, the continued resistance from some state legislatures, like Pennsylvania, underscores the complex and uneven regulatory landscape that remains a key risk factor.

What we're watching

State Resistance
Pennsylvania lawmakers' continued opposition to cannabis reform, despite the federal rescheduling, suggests potential roadblocks for Jushi's expansion plans in that state and highlights the ongoing divergence between federal and state policy.
Research Impact
The extent to which federally supported research into cannabis will translate into commercially viable products and therapies remains uncertain, and will be a key indicator of the rescheduling's long-term economic impact.
Investment Flow
Whether the reduced regulatory burden and increased legitimacy will spur significant new investment into the cannabis sector, and specifically benefit Jushi's vertically integrated model, is a critical factor to monitor.